$3.5
+0.17
(+5.11%)▲
Revenue is up for the last 3 quarters, 3.0K → 65.0K (in $), with an average increase of 59.7% per quarter
Netprofit is down for the last 2 quarters, -8.39K → -132.63M (in $), with an average decrease of 1579392.7% per quarter
In the last 1 year, Seagen Inc has given 39.6% return, outperforming this stock by 70.2%
4.86%
Downside
Day's Volatility :5.26%
Upside
0.43%
49.43%
Downside
52 Weeks Volatility :79.75%
Upside
59.95%
Period | Lyell Immunopharma, Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 57.66% | 0.9% | -8.3% |
6 Months | -10.94% | -6.8% | -6.5% |
1 Year | -30.56% | 0.4% | -6.1% |
3 Years | -79.28% | 27.3% | 21.8% |
Market Capitalization | 873.6M |
Book Value | $3.14 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.88 |
Wall Street Target Price | 7.25 |
Profit Margin | -216.09% |
Operating Margin TTM | -215.0% |
Return On Assets TTM | -11.59% |
Return On Equity TTM | -21.85% |
Revenue TTM | 84.2M |
Revenue Per Share TTM | 0.34 |
Quarterly Revenue Growth YOY | -88.2% |
Gross Profit TTM | 84.7M |
EBITDA | -162.2M |
Diluted Eps TTM | -0.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.15 |
EPS Estimate Next Year | -1.37 |
EPS Estimate Current Quarter | -0.28 |
EPS Estimate Next Quarter | -0.29 |
What analysts predicted
Upside of 107.14%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 657.0K | - |
Net Income | -129.4M | - |
Net Profit Margin | -19.7K% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 7.8M | ↑ 1080.52% |
Net Income | -204.5M | ↑ 58.04% |
Net Profit Margin | -2.6K% | ↑ 17055.78% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 10.7M | ↑ 37.31% |
Net Income | -250.2M | ↑ 22.37% |
Net Profit Margin | -2.3K% | ↑ 286.84% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 84.7M | ↑ 695.15% |
Net Income | -183.1M | ↓ 26.82% |
Net Profit Margin | -216.24% | ↑ 2133.23% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 2.8M | ↑ 2.43% |
Net Income | -83.7M | ↑ 71.27% |
Net Profit Margin | -3.0K% | ↓ 1192.14% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 553.0K | ↓ 80.4% |
Net Income | -68.1M | ↓ 18.59% |
Net Profit Margin | -12.3K% | ↓ 9356.41% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 35.7M | ↑ 6363.11% |
Net Income | -36.3M | ↓ 46.7% |
Net Profit Margin | -101.63% | ↑ 12220.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.0K | ↓ 99.99% |
Net Income | -70.3M | ↑ 93.41% |
Net Profit Margin | -2.3M% | ↓ 2341698.37% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 48.4K | ↑ 1512.87% |
Net Income | -8.4K | ↓ 99.99% |
Net Profit Margin | -17.35% | ↑ 2341782.65% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 65.0K | ↑ 34.34% |
Net Income | -132.6M | ↑ 1579392.68% |
Net Profit Margin | -204.0K% | ↓ 204028.8% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 555.6M | - |
Total Liabilities | 147.6M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 908.3M | ↑ 63.47% |
Total Liabilities | 189.8M | ↑ 28.64% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 24.13% |
Total Liabilities | 197.6M | ↑ 4.1% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 937.6M | ↓ 16.84% |
Total Liabilities | 104.3M | ↓ 47.22% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 5.92% |
Total Liabilities | 197.6M | ↓ 6.72% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 4.91% |
Total Liabilities | 190.9M | ↓ 3.42% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 4.7% |
Total Liabilities | 153.6M | ↓ 19.5% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 977.3M | ↓ 4.35% |
Total Liabilities | 157.2M | ↑ 2.35% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 937.6M | ↓ 4.06% |
Total Liabilities | 104.3M | ↓ 33.66% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 880.5M | ↓ 6.09% |
Total Liabilities | 96.6M | ↓ 7.37% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 39.5M | - |
Investing Cash Flow | -422.4M | - |
Financing Cash Flow | 351.2M | - |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -160.9M | ↓ 507.54% |
Investing Cash Flow | -273.5M | ↓ 35.25% |
Financing Cash Flow | 476.8M | ↑ 35.78% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -126.2M | ↓ 21.52% |
Investing Cash Flow | -121.6M | ↓ 55.55% |
Financing Cash Flow | 401.2M | ↓ 15.84% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -33.2M | ↑ 29.93% |
Investing Cash Flow | -73.9M | ↓ 48.99% |
Financing Cash Flow | 7.4M | ↓ 1493.41% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -47.9M | ↑ 44.25% |
Investing Cash Flow | -26.1M | ↓ 64.65% |
Financing Cash Flow | 2.6M | ↓ 65.47% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -44.3M | ↓ 7.35% |
Investing Cash Flow | 25.0M | ↓ 195.78% |
Financing Cash Flow | 2.5M | ↓ 3.84% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -37.1M | ↓ 16.31% |
Investing Cash Flow | -57.1M | ↓ 328.17% |
Financing Cash Flow | 4.8M | ↑ 93.73% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -46.2M | ↑ 14.76% |
Investing Cash Flow | 32.2M | - |
Financing Cash Flow | -69.0K | ↓ 108.0% |
Sell
Neutral
Buy
Lyell Immunopharma, Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Lyell Immunopharma, Inc | 50.86% | -10.94% | -30.56% | -79.28% | -79.28% |
![]() Moderna, Inc. | 0.28% | -25.82% | -4.84% | 117.92% | 601.67% |
![]() Regeneron Pharmaceuticals, Inc. | -7.87% | -2.05% | 17.39% | 22.45% | 137.1% |
![]() Seagen, Inc. | -1.61% | 61.18% | 39.62% | 26.01% | 217.64% |
![]() Vertex Pharmaceuticals Incorporated | -3.63% | 5.09% | 23.88% | 20.49% | 123.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Lyell Immunopharma, Inc | 1.78 | NA | NA | -1.15 | -0.22 | -0.12 | 0.0 | 3.14 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.91 | 19.91 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.18 | 26.18 | 0.41 | 14.61 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Lyell Immunopharma, Inc | Buy | $873.6M | -79.28% | 1.78 | -216.09% |
![]() Moderna, Inc. | Buy | $49.1B | 601.67% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $80.7B | 137.1% | 19.91 | 33.81% |
![]() Seagen, Inc. | Hold | $36.5B | 217.64% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.3B | 123.04% | 26.18 | 35.4% |
MWG Management Ltd.
Orland Properties Ltd
Vanguard Group Inc
BlackRock Inc
Foresite Capital Management IV, LLC
State Street Corporation
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. The Company focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes. Lyell is based in South San Francisco, Seattle and Bothell, Washington.
Organization | Lyell Immunopharma, Inc |
Employees | 274 |
CEO | Dr. Richard D. Klausner M.D. |
Industry | Services |
THESEUS PHARMACEUTICALS, INC.
$8.78
+1.97%
Tilly's Inc
$6.45
-12.6%
RUMBLEON INC
$12.22
+11.39%
H&E Equipment Services Inc
$39.52
+8.33%
Barrett Business Services Inc
$87.15
+3.42%
Healthcare Services Group Inc
$13.92
+3.42%
America's Car-Mart Inc
$88.95
+11.08%
JIANZHI EDUCATION TECHNOLOGY GROUP COMPANY LTD.
$1.01
+5.09%
TELESAT CORP
$7.42
+5.03%